CD95 inhib 
Welcome,         Profile    Billing    Logout  
 3 Companies  3 Products   3 Products   5 Diseases   2 Trials   52 News 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ONL1204 / ONL Therap
NCT05730218: A Phase 2 Study to Assess the Safety and Efficacy of Intravitreal ONL1204 Ophthalmic Solution in Subjects With Mac-off Retinal Detachment

Completed
2
136
US
ONL1204 Ophthalmic Solution, Sham treatment
ONL Therapeutics
Rhegmatogenous Retinal Detachment - Macula Off
02/24
02/24
NCT06659445: Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

Not yet recruiting
2
324
NA
ONL1204 Opthalmic solution, Avacincaptad Pegol intravitreal solution, Sham
ONL Therapeutics
Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)
11/27
11/27
NCT04744662: ONL1204 Ophthalmic Solution in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration

Completed
1
28
RoW
ONL1204 Ophthalmic solution, sham injection
ONL Therapeutics
Geographic Atrophy
02/24
02/24
NCT05160805: A Phase 1b Study of ONL1204 Ophthalmic Solution in Patients with Progressing Open Angle Glaucoma

Completed
1
25
RoW
ONL1204 Ophthalmic solution (Dose A), ONL1204 Ophthalmic solution (Dose B), Sham procedure
ONL Therapeutics
Open Angle Glaucoma
04/24
04/24
AB-1015 / ArsenalBio
NCT05617755: AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients with Platinum Resistant Epithelial Ovarian Cancer

Active, not recruiting
1
19
US
AB-1015, Integrated Circuit T (ICT) cells
Arsenal Biosciences, Inc.
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Genital Neoplasm, Female, Abdominal Neoplasm, Recurrence
09/24
02/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ONL1204 / ONL Therap
NCT05730218: A Phase 2 Study to Assess the Safety and Efficacy of Intravitreal ONL1204 Ophthalmic Solution in Subjects With Mac-off Retinal Detachment

Completed
2
136
US
ONL1204 Ophthalmic Solution, Sham treatment
ONL Therapeutics
Rhegmatogenous Retinal Detachment - Macula Off
02/24
02/24
NCT06659445: Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

Not yet recruiting
2
324
NA
ONL1204 Opthalmic solution, Avacincaptad Pegol intravitreal solution, Sham
ONL Therapeutics
Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)
11/27
11/27
NCT04744662: ONL1204 Ophthalmic Solution in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration

Completed
1
28
RoW
ONL1204 Ophthalmic solution, sham injection
ONL Therapeutics
Geographic Atrophy
02/24
02/24
NCT05160805: A Phase 1b Study of ONL1204 Ophthalmic Solution in Patients with Progressing Open Angle Glaucoma

Completed
1
25
RoW
ONL1204 Ophthalmic solution (Dose A), ONL1204 Ophthalmic solution (Dose B), Sham procedure
ONL Therapeutics
Open Angle Glaucoma
04/24
04/24
AB-1015 / ArsenalBio
NCT05617755: AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients with Platinum Resistant Epithelial Ovarian Cancer

Active, not recruiting
1
19
US
AB-1015, Integrated Circuit T (ICT) cells
Arsenal Biosciences, Inc.
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Genital Neoplasm, Female, Abdominal Neoplasm, Recurrence
09/24
02/27

Download Options